Hostname: page-component-76fb5796d-skm99 Total loading time: 0 Render date: 2024-04-26T23:06:39.621Z Has data issue: false hasContentIssue false
  • English
  • Français

Comment on the London/Toronto Study of Alprazolam and Exposure in Panic Disorder with Agoraphobia

Published online by Cambridge University Press:  02 January 2018

David A. Spiegel ,
Martin Roth ,
Myrna Weissman ,
Philip Lavori ,
Jack Gorman ,
John Rush  and
James Ballenger
David A. Spiegel*
Affiliation:
Department of Psychiatry and Behavioral Medicine, University of Illinois College of Medicine at Peoria, IL, USA
Martin Roth
Affiliation:
University of Cambridge
Myrna Weissman
Affiliation:
Department of Psychiatry and Epidemiology, College of Physicians & Surgeons, Columbia University, New York, USA
Philip Lavori
Affiliation:
Biological Studies Unit, College of Physicians & Surgeons, Columbia University, New York, USA
Jack Gorman
Affiliation:
Cooperative Studies Coordinating Center, Department of Veterans Affairs Medical Center, Palo Alto, CA, USA
John Rush
Affiliation:
Department of Psychiatry, University of Texas, Southwestern Medical Center at Dallas, TX, USA
James Ballenger
Affiliation:
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA
*
∗Correspondence
Get access Rights & Permissions [Opens in a new window]

Extract

The study reported by Marks et al is of considerable importance, since it is the largest clinical trial to date comparing the combination of a benzodiazepine and behaviour therapy to either component alone, and the first combined treatment trial to use alprazolam as the pharmacological agent. It was an ambitious project that was apparently well run, and the findings should be of wide interest. However, the potential value of the study is limited by the method, the patient sample, and the analysis and presentation of the data.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 162 , Issue 6 , June 1993 , pp. 788 - 789
Copyright
Copyright © The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Foa, E. B., Grayson, J. B., Steketee, G. S., et al (1983) Success and failure in the behavioral treatment of obsessive-compulsives. Journal of Consulting and Clinical Psychology, 51, 287–297.Google Scholar
Hafner, J. & Marks, I. (1976) Exposure in vivo of agoraphobics: contributions of diazepam, group exposure, and anxiety evocation. Psychological Medicine, 6, 71–88.CrossRefGoogle ScholarPubMed
Katschnig, H., Stolk, J. M., Klerman, G. L., et al (1991) Discontinuation and long term follow up of participants in a clinical drug trial for panic disorder. In Proceedings of the 5th World Congress of Biological Psychiatry, Vol. 1, (eds Racagni, G., Brunello, N. & Fukuda, T.), pp. 657–660. Amsterdam: Excerpta Medica.Google Scholar
Marks, I. M., Viswanathan, R., Lipsedge, M. S., et al (1972) Enhanced relief of phobias by flooding during waning diazepam. British Journal of Psychiatry, 121, 493–505.CrossRefGoogle ScholarPubMed
Marks, I. M., Lelliott, P., Başoǧlu, M., et al (1988) Clomipramine, self-exposure and therapist-aided exposure for obsessive-compulsive rituals. British Journal of Psychiatry, 152, 522–534.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.